Committee for Medicinal Products for Human Use (CHMP): 23-26 February 2026, European Medicines Agency, Amsterdam, the Netherlands, from 23 February 2026 to 26 February 2026

Annex to 23-26 February 2026 CHMP Minutes

Minutes of the CHMP meeting 23-26 February 2026

List of clinical evaluation consultation procedure (CECP) opinions issued for medical devices awaiting finalisation of conformity assessment

Human medicines European public assessment report (EPAR): Blenrep, belantamab mafodotin, Date of authorisation: 23/07/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Bysumlog, insulin lispro, Date of authorisation: 06/05/2026, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Tezspire, tezepelumab, Date of authorisation: 19/09/2022, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Vijoice, alpelisib, Date of authorisation: 15/07/2026, Status: Authorised

Orphan designation: daratumumab Treatment of AL amyloidosis, 25/05/2018 Withdrawn

Human medicines European public assessment report (EPAR): Darzalex, daratumumab, Date of authorisation: 20/05/2016, Revision: 30, Status: Authorised